Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd-Chiari syndrome on warfarin.
Akash ShuklaAbhinav JainVinit KahalekarSheetal BendkhaleNithya GogtayUrmila ThatteShobna BhatiaPublished in: Hepatology international (2019)
The presence of mutations in VKORC1 or CYP2C9 is associated with increased risk of bleeding in patients with BCS on warfarin. Such patients with SNPs of CY2C9 or VKORC1 haplotype should be monitored intensively while receiving warfarin.